Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TESSERACT: TBI and H-RT with Atezolizumab and Chemotherapy in ES-SCLC
NCT06110572Phase 2Recruiting
- Sponsor
- Vanderbilt-Ingram Cancer Center
- Start
- Apr 2024
- Primary completion
- Jun 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of atezolizumab in small cell lung cancer (SCLC), sponsored by Vanderbilt-Ingram Cancer Center. Started Apr 2024; status: recruiting.
02
Drugs
atezolizumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT06110572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06110572.